Type2 Diabetes Mellitus
Conditions
Interventions
investigational material(s)
Generic name etc : KRP-104
INN of investigational material :
Therapeutic category code : 396 Antidiabetic agents
Dosage and Administration for Investigational material : t
Sponsors
Kyorin Pharmaceutical Co.,LTD
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria; -Diagnosis of type 2 diabetes -Outpatients etc.
Exclusion criteria
Exclusion criteria: Exclusion criteria; -Diagnosis of type 1 diabetes -Patients with malignant tumor -Patients with severe hepatic dysfunction -Patients with severe renal dysfunction -Patients with severe blood dyscraaia -Patients with severe cardiovascular or pulmonary dysfunction etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c change from baseline on HbA1c at 12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| FPG,glycoalbumin,insulin etc. change from baseline on FPG at 12 weeks change from baseline on glycoalbumin at 12 weeks change from baseline on insulin at 12 weeks etc. | — |
Outcome results
None listed